Article Information
History
- September 20, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Joseph J. Sabatino Jr.1,*,
- Kristen Mittl1,
- William Rowles1,
- Kira Mcpolin1,
- Jayant V. Rajan2,
- Colin R. Zamecnik1,
- Ravi Dandekar1,
- Bonny D. Alvarenga1,
- Rita P. Loudermilk1,
- Chloe Gerungan1,
- Collin M. Spencer1,
- Sharon A. Sagan1,
- Danillo G. Augusto1,4,
- Jessa Alexander1,
- Jill A. Hollenbach1,3,
- Michael R. Wilson1,
- Scott S. Zamvil1 and
- Riley Bove1,*
- 1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
- 2Division of Experimental Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA
- 3Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
- 4Programa de Pós-Graduação em Genética, Universidade Federal do Paraná, Curitiba, Brazil
- ↵*Corresponding authors: J Sabatino, email: joseph.sabatinojr{at}ucsf.edu. R Bove, email: riley.bove{at}ucsf.edu
Posted September 20, 2021.
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
